Streetbeat News

Revenues

JKHY

Jack Henry & Associates (NASDAQ:JKHY) has been analyzed by five analysts, showing a range of sentiments from somewhat bullish to indifferent. The average 12-month price target is $189.6, up 4.46% from the previous target. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position. Jack Henry is a leading provider of core processing services for banks and credit unions, with strong net margins and efficient asset use, but faces challenges in revenue growth and return on equity.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

CCI

Crown Castle (NYSE:CCI) has been analyzed by 8 analysts, showing a range of ratings from bullish to indifferent. Recent analyst actions include both raised and lowered price targets, with an average 12-month target of $116.75, up 4.35% from the previous average. Despite positive analyst sentiment, Crown Castle faces financial challenges, including a -12.91% revenue decline, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

SPY

Retail inventories in the USA, excluding autos, increased by 0.5% in August, surpassing the estimated 0.4% and matching the prior month's growth.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

SPY

The NAHB Housing Market Index for October remained steady at 43, matching expectations and showing no change from the previous month. This indicates a stable sentiment in the housing market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) has been evaluated by 8 analysts over the past three months, with all ratings being bullish. The average 12-month price target remains at $10.00. Despite strong revenue growth, the company faces challenges with profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

SPY

The USA Business Inventories for August increased by 0.3%, matching both the estimate and the prior month's figure.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

DIA

IWM

QQQ

SPY

TSM

Major indexes rose due to strong performance in chip stocks after TSM's earnings, an ECB rate cut, and better-than-expected US retail sales.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:49 pm

CNPOF

CNTMF

RIV Capital has partnered with cannabis wholesale platform Nabis to enhance distribution in New York. This partnership aims to expand RIV's reach and efficiency in the growing New York cannabis market. The merger with Cansortium is also expected to boost RIV's market presence.

Portfolio Pulse from Nina Zdinjak

October 17, 2024 | 1:37 pm

TSM

XRT

The European Central Bank (ECB) has cut interest rates, which is a significant monetary policy move. Chip stocks have gained following strong guidance from Taiwan Semiconductor Manufacturing Company (TSM). Additionally, September retail sales have exceeded estimates, indicating robust consumer spending.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:36 pm

TVGN

Tevogen Bio Oncology projects $1 billion in revenue for its launch year and $10-$14 billion over five years, driven by its treatment for SARS-CoV-2 in cancer patients. The company also plans to expand into additional therapeutic areas and has long-term innovation goals.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:34 pm